Nektar Therapeutics
General ticker "NKTR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Nektar Therapeutics follows the US Stock Market performance with the rate: 29.0%.
Estimated limits based on current volatility of 2.2%: low 70.61$, high 73.80$
Factors to consider:
- Total employees count: 63 (+3.3%) as of 2025
- US accounted for 1.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Insufficient capital, Market competition, Manufacturing risks
- Current price 18.5% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.24$, 61.40$]
- 2026-12-31 to 2027-12-31 estimated range: [11.41$, 36.16$]
Financial Metrics affecting the NKTR estimates:
- Negative: with PPE of -4.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -28.53 <= 0.28
- Positive: Investing cash flow per share per price, % of -0.16 > -0.64
- Negative: negative Net income
- Positive: 18.97 < Shareholder equity ratio, % of 32.04 <= 42.26
- Negative: Interest expense per share per price, % of 3.58 > 3.34
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term NKTR quotes
Long-term NKTR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $90.12MM | $98.43MM | $55.23MM |
| Operating Expenses | $353.81MM | $203.62MM | $195.33MM |
| Operating Income | $-263.68MM | $-105.20MM | $-140.10MM |
| Non-Operating Income | $-12.57MM | $-14.00MM | $-15.38MM |
| Interest Expense | $25.33MM | $28.11MM | $26.18MM |
| R&D Expense | $114.16MM | $120.91MM | $117.33MM |
| Income(Loss) | $-276.26MM | $-119.20MM | $-155.49MM |
| Taxes | $-0.20MM | $-0.24MM | $-0.14MM |
| Other Income(Loss) | $0.00MM | $0.00MM | $-8.73MM |
| Net Income(Loss)* | $-276.06MM | $-118.96MM | $-164.08MM |
| Stockholders Equity | $130.99MM | $60.74MM | $89.83MM |
| Inventory | $16.10MM | $0.00MM | $0.00MM |
| Assets | $398.03MM | $303.85MM | $280.41MM |
| Operating Cash Flow | $-192.61MM | $-175.71MM | $-208.51MM |
| Capital expenditure | $0.86MM | $1.47MM | $0.17MM |
| Investing Cash Flow | $139.56MM | $142.57MM | $-1.20MM |
| Financing Cash Flow | $0.03MM | $42.12MM | $180.57MM |
| Earnings Per Share** | $-21.79 | $-8.68 | $-9.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.